Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives $14.00 Average PT from Brokerages

Kalaris Therapeutics Inc. (NASDAQ:KLRS) has been assigned an average recommendation of “Moderate Buy” from the six brokerages that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $14.00.

Several brokerages have weighed in on KLRS. Citigroup reissued an “outperform” rating on shares of Kalaris Therapeutics in a research note on Thursday, December 18th. Citizens Jmp initiated coverage on Kalaris Therapeutics in a report on Monday, November 3rd. They set a “market outperform” rating and a $20.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kalaris Therapeutics in a research note on Monday, December 29th. Chardan Capital started coverage on shares of Kalaris Therapeutics in a research report on Tuesday, December 23rd. They set a “buy” rating and a $19.00 price objective on the stock. Finally, Wall Street Zen upgraded Kalaris Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, December 20th.

Kalaris Therapeutics Stock Down 0.2%

Kalaris Therapeutics stock opened at $9.79 on Friday. Kalaris Therapeutics has a 52-week low of $2.14 and a 52-week high of $12.90. The firm’s fifty day moving average is $7.96 and its 200 day moving average is $5.37. The company has a market cap of $183.07 million, a price-to-earnings ratio of -2.60 and a beta of -0.09.

Kalaris Therapeutics (NASDAQ:KLRS) last posted its earnings results on Wednesday, November 12th. The company reported ($0.64) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.02.

Institutional Trading of Kalaris Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in KLRS. XTX Topco Ltd acquired a new position in shares of Kalaris Therapeutics in the 2nd quarter valued at $65,000. Fortis Capital Advisors LLC purchased a new stake in Kalaris Therapeutics during the 3rd quarter valued at about $231,000. Belpointe Asset Management LLC acquired a new position in shares of Kalaris Therapeutics in the third quarter valued at about $231,000. Johnson Financial Group Inc. acquired a new position in shares of Kalaris Therapeutics in the third quarter valued at about $58,000. Finally, Bridgeway Capital Management LLC purchased a new position in shares of Kalaris Therapeutics in the third quarter worth about $130,000. Hedge funds and other institutional investors own 66.05% of the company’s stock.

Kalaris Therapeutics Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.